Overview

A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery.

Status:
Withdrawn

Trial end date:
1999-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine an effective dose of epoetin alfa to be administered prior to surgery, to decrease the need for blood transfusions during hip replacement. Epoetin alfa is a genetically engineered protein that stimulates red blood cell production.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen-Ortho Inc., Canada

Treatments:

Epoetin Alfa